Suchen
Vyne Therapeutics Inc
VYNEZur Watchlist hinzufügen
0.681USD
+0.030+4.66%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
22.74MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vyne Therapeutics Inc Unternehmen
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc Informationen
BörsenkürzelVYNE
Name des UnternehmensVyne Therapeutics Inc
IPO-datumJan 25, 2018
CEODomzalski (David)
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeJan 25
Addresse685 Route 202/206 N., Suite 301
StadtBRIDGEWATER
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl08807
Telefon18007757936
Websitehttps://vynetherapeutics.com/
BörsenkürzelVYNE
IPO-datumJan 25, 2018
CEODomzalski (David)
Führungskräfte von Vyne Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Vyne Therapeutics Inc?
Die fünf größten Anteilseigner von Vyne Therapeutics Inc sind: Mr. Tyler Zeronda
Wie viele Institutionen halten Anteile an Vyne Therapeutics Inc (VYNE)?
Mit Stand vom 2026Q1 halten 92 Institutionen Anteile an Vyne Therapeutics Inc, mit einem Gesamtmarktwert von etwa 11.08M, was 33.26% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1672969.00 gestiegen.